Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling
F Buontempo, E Orsini, LR Martins, I Antunes, A Lonetti… - Leukemia, 2014 - nature.com
Constitutively active casein kinase 2 (CK2) signaling is a common feature of T-cell acute
lymphoblastic leukemia (T-ALL). CK2 phosphorylates PTEN (phosphatase and tensin …
lymphoblastic leukemia (T-ALL). CK2 phosphorylates PTEN (phosphatase and tensin …
Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia
LR Martins, P Lúcio, A Melao, I Antunes, BA Cardoso… - Leukemia, 2014 - nature.com
Chronic lymphocytic leukemia (CLL) remains a therapeutic challenge. New immuno-
chemotherapeutic approaches have had a significant impact, improving overall survival …
chemotherapeutic approaches have had a significant impact, improving overall survival …
[HTML][HTML] Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 …
F Buontempo, E Orsini, A Lonetti, A Cappellini… - Oncotarget, 2016 - ncbi.nlm.nih.gov
The proteasome inhibitor bortezomib is a new targeted treatment option for refractory or
relapsed acute lymphoblastic leukemia (ALL) patients. However, a limited efficacy of …
relapsed acute lymphoblastic leukemia (ALL) patients. However, a limited efficacy of …
Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
A Richter, C Roolf, M Hamed, YS Gladbach, S Sender… - BMC cancer, 2019 - Springer
Background The tumor suppressor protein phosphatase and tensin homolog (PTEN) is a
key regulator of the PI3K/AKT pathway which is frequently altered in a variety of tumors …
key regulator of the PI3K/AKT pathway which is frequently altered in a variety of tumors …
Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia
S Lust, B Vanhoecke, M Van Gele, J Boelens… - Anticancer …, 2009 - ar.iiarjournals.org
Background: Chronic lymphocytic leukemia (CLL) is an incurable disease with a natural
history of increasing resistance to chemotherapy. A novel approach to overcome …
history of increasing resistance to chemotherapy. A novel approach to overcome …
Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells
C Paiva, JC Godbersen, RS Soderquist, T Rowland… - PLoS …, 2015 - journals.plos.org
CDK (cyclin-dependent kinase) inhibitors have shown remarkable activity in CLL, where its
efficacy has been linked to inhibition of the transcriptional CDKs (7 and 9) and deregulation …
efficacy has been linked to inhibition of the transcriptional CDKs (7 and 9) and deregulation …
[HTML][HTML] The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia
RD Mendes, K Canté-Barrett, R Pieters… - …, 2016 - ncbi.nlm.nih.gov
The tumor suppressor phosphatase and tensin homolog (PTEN) negatively regulates
phosphatidylinositol 3-kinase (PI3K)-AKT signaling and is often inactivated by mutations …
phosphatidylinositol 3-kinase (PI3K)-AKT signaling and is often inactivated by mutations …
[HTML][HTML] Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN …
AM Gomes, MVD Soares, P Ribeiro, J Caldas… - …, 2014 - ncbi.nlm.nih.gov
Adult B-cell acute lymphoblastic leukemia remains a major therapeutic challenge, requiring
a better characterization of the molecular determinants underlying disease progression and …
a better characterization of the molecular determinants underlying disease progression and …
CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress
LM Sarmento, V Póvoa, R Nascimento, G Real… - Oncogene, 2015 - nature.com
Abstract Checkpoint kinase 1 (CHK1) is a key component of the ATR (ataxia telangiectasia-
mutated and Rad3-related)-dependent DNA damage response pathway that protect cells …
mutated and Rad3-related)-dependent DNA damage response pathway that protect cells …
Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia
LR Martins, P Lúcio, MC Silva… - Blood, The Journal …, 2010 - ashpublications.org
Expression of protein kinase CK2 is frequently deregulated in cancer and mounting
evidence implicates CK2 in tumorigenesis. Here, we show that CK2 is overexpressed and …
evidence implicates CK2 in tumorigenesis. Here, we show that CK2 is overexpressed and …